Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
7.40
-0.02 (-0.27%)
At close: Jul 26, 2024, 4:00 PM
7.55
+0.15 (2.03%)
After-hours: Jul 26, 2024, 5:06 PM EDT
Mesoblast Revenue
Mesoblast had revenue of $1.69M in the quarter ending December 31, 2023, a decrease of -11.72%. This brings the company's revenue in the last twelve months to $7.47M, down -2.47% year-over-year. In the fiscal year ending June 30, 2023, Mesoblast had annual revenue of $7.50M, down -26.54%.
Revenue (ttm)
$7.47M
Revenue Growth
-2.47%
P/S Ratio
129.57
Revenue / Employee
$87,386
Employees
83
Market Cap
939.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
| Jun 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Embecta | 1.13B |
| Pacira BioSciences | 681.75M |
| Cronos Group | 93.03M |
| Silence Therapeutics | 33.86M |
| 4D Molecular Therapeutics | 20.45M |
| Perspective Therapeutics | -304.00K |
MESO News
- 3 days ago - FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) - GlobeNewsWire
- 4 days ago - Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain - GlobeNewsWire
- 17 days ago - Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) - GlobeNewsWire
- 25 days ago - Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week - GlobeNewsWire
- 7 weeks ago - Mesoblast Corporate Presentation at Investor Conference - GlobeNewsWire
- 3 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 - GlobeNewsWire
- 4 months ago - United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) - GlobeNewsWire
- 4 months ago - Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer - GlobeNewsWire